Detalhe da pesquisa
1.
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
Blood
; 137(8): 1050-1060, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32959058
2.
Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study.
Haematologica
; 107(10): 2329-2343, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35021602
3.
Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.
Expert Rev Proteomics
; 17(1): 1-10, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31945303
4.
Histone Modification Patterns Using RPPA-Based Profiling Predict Outcome in Acute Myeloid Leukemia Patients.
Proteomics
; 18(8): e1700379, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29505696
5.
Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial.
Cancers (Basel)
; 16(8)2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38672531
6.
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA.
Proteomics Clin Appl
; 16(2): e2100072, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34719869
7.
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences.
Leukemia
; 36(3): 712-722, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625713